Adolescent- and adult-onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020.
Orlane MagnierIsabelle SchiffJustine CristanteOlivier ChabreMelanie VelosoJean-Luc BossonAnne-Sophie DefachellesCamille CorderoChristine Do CaoEstelle ThebaudDelphine DruiPablo BerlangaBenoit DumontPhilippe ChastagnerJulie TandonnetMarion GambartSarah JannierClaire PluchartLeslie AndryVéronique LaithierSébastien KleinLiana CarausuTasmine AkbaralyJamie ProbertRaphaelle Habert-DantignyDominique PlantazPublished in: Pediatric blood & cancer (2024)
Outcomes were better for patients with localized tumor than for patients with metastases. For patients with localized tumor, in terms of survival, surgical treatment was the best therapeutic option. Multimodal treatment with chemotherapy, surgery, radiotherapy, and immunotherapy-based maintenance allowed long-term survival for some patients. Adolescent- and adult-onset neuroblastoma appeared to have specific characteristics associated with poorer outcomes compared to pediatric neuroblastoma. Nevertheless, complete disease control improved survival. The presence of a neuroblastic component in pheochromocytoma should be considered when making therapeutic management decisions. The development of specific tools/resources (Tumor Referral Board, Registry, biology, and trials with new agents or strategies) may help to improve outcomes for patients.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- primary care
- prognostic factors
- mental health
- peritoneal dialysis
- minimally invasive
- radiation therapy
- type diabetes
- patient reported outcomes
- metabolic syndrome
- acute coronary syndrome
- pain management
- radiation induced
- atrial fibrillation
- patient reported
- replacement therapy
- percutaneous coronary intervention